CStone Pharmaceuticals (2616) released details regarding its board of directors and the composition of its board committees on November 1, 2025. The board comprises one executive director, two non-executive directors, and three independent non-executive directors. The executive director, who also serves as chief executive officer, is joined by a chairman and two additional non-executive directors, with three more directors holding independent non-executive roles.

Five committees are in place to oversee various corporate matters: Audit, Compensation, Nomination, Strategy, and Investment. The chairperson and member assignments of these committees are led by different directors, ensuring diversified leadership and governance. The announced structure indicates that each director holds at least one committee responsibility, underscoring a shared approach to strategic planning, investment oversight, financial auditing, compensation review, and board nominations.